Despite myriad innovations in design, conduct, and supporting technologies, clinical trials are becoming more complex, keeping them prohibitively expensive and slow. As a result, the clinical trials ecosystem is not producing evidence about medical interventions fast enough to keep pace with science and improve population health. There is a continued need for a dedicated convener who understands the entire trials enterprise and can create the alignment and infrastructure necessary to help all invested parties make vital improvements. The Clinical Trials Transformation Initiative (CTTI) is a public-private partnership, co-founded by Duke University and the US Food and Drug Administration, with a mission to develop and drive the adoption of practices that will increase the quality and efficiency of clinical trials. For over 15 years, CTTI has successfully spurred change in the clinical trials enterprise, convening thousands of individuals from over 700 organizations as thought partners, co-developers, and co-implementers to produce a significant body of work. CTTI has created and disseminated over 30 sets of evidence-supported, consensus-driven recommendations addressing critical trial quality and efficiency, alongside more than 80 implementation tools to support stakeholders in putting best practices into action. CTTI resources have been cited in FDA and global guidance documents and have inspired smarter, more efficient trial design choices across countless sponsors. CTTI has also emerged as a north star for the enterprise in the five pillars of its Transforming Trials 2030 vision, which stipulates that by 2030 trials will be patient-centric and accessible, integrated into healthcare settings, designed with a quality approach, leveraging all available data, and improving population health. CTTI has succeeded in creating a truly inclusive, participatory culture in which the views and interests of constituents are fairly represented and valued. No one organization can enact systemic change; therefore, no one organization controls any CTTI activity. By engaging passionate, committed people, project execution is enhanced, collective ownership of solutions is established, and recommendations are implemented. For the 2024-2029 period, CTTI will continue to build on this progress through the following specific aims: maintain an administrative and scientific infrastructure to implement all related activities under this collaborative effort; provide leadership in the establishment of goals, coordination across efforts, measurement of progress, adaptability and resilience to promote the strength and impact of the clinical trials enterprise; create evidence-based recommendations, implementation resources, and shared knowledge to help interested parties across the clinical trials enterprise realize the Transforming Trials 2030 vision; and drive innovation through strategic communication and engagement efforts that support CTTI recommendations, thought lea...